Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NCT02015780 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Due to potential concerns about liver safety (See Detailed Description)

Conditions

Type 2 Diabetes Mellitus
Chronic Kidney Disease

Interventions

DRUG: Fasiglifam
DRUG: Placebo
DRUG: Antihyperglycemic therapy

Sponsor

Takeda